An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
NCT00250601
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
460
Enrollment
INDUSTRY
Sponsor class
Conditions
Depressive Disorder
Interventions
DRUG:
Saredutant succinate (SR48968C)
Sponsor
Sanofi